Repligen Corp (STU:RGN)
€ 126.35 +7.5 (+6.31%) Market Cap: 7.14 Bil Enterprise Value: 7.06 Bil PE Ratio: 160.27 PB Ratio: 3.86 GF Score: 84/100

Repligen Corp at SVB Leerink Global Healthcare Conference (Virtual) Transcript

Feb 26, 2021 / 05:00PM GMT
Release Date Price: €168 (-4.46%)
Puneet Souda
SVB Leerink LLC, Research Division - MD of Life Science Tools & Diagnostics and Senior Research Analyst

Okay. Great. Welcome, everyone. I'm Puneet Souda, SVB Leerink tools and diagnostic analyst here. And it's a pleasure to be hosting Repligen management team. Joining us from Repligen is Tony Hunt, CEO; and Jon Snodgres, CFO. Hey guys, welcome. Glad to have you here.

Anthony J. Hunt
Repligen Corporation - CEO, President & Director

Puneet, good to see you.

Puneet Souda
SVB Leerink LLC, Research Division - MD of Life Science Tools & Diagnostics and Senior Research Analyst

Great. So just before we get started, I mean, to me, look, Repligen is a high-growth company in the bioprocessing space that is benefiting COVID vaccine ramp and is increasingly seeing growth from high-growth markets of cell and gene therapy. So obviously, a lot to cover here. Please send me questions through the chat if you have any or through e-mail, and we'll cover them during the session.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot